Dersimelagon not checked
Tanabe Pharma America, Inc. · MT-7117
FollowEvery change as it happens, and a Monday email
Trials
1 active
12 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- EPP, XLP
- Main trialPhase 3
- “To evaluate the long-term safety and tolerability of oral dersimelagon.”In the company’s words, NCT05005975 on ClinicalTrials.gov
- Other names
- MT-7117
Coming up1
- Dec 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials12
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | Dec 2027 | Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP) | |
| Phase 3Completed | 14 Dec 2021 | Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria or X-Linked Protoporphyria | |
| Phase 3Completed | 14 Apr 2026 | INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP | |
| Phase 2Completed | 28 Sep 2019 | Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria | |
| Phase 2Completed | 17 Jan 2024 | Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Diffuse Cutaneous Systemic Sclerosis | |
| Phase 1Completed | 11 May 2018 | Mass Balance Study With MT-7117 | |
| Phase 1Completed | 22 Dec 2018 | Relative Bioavailability and Drug-drug Interaction Study With MT-7117 and a Proton Pump Inhibitor | |
| Phase 1Completed | 16 Feb 2021 | Study to Assess Pharmacokinetics, Safety, and Tolerability of MT-7117 in Subjects With Normal and Impaired Hepatic Function | |
| Phase 1Completed | 4 Dec 2021 | PK Study in Subjects With Renal Impairment (Severe and if Required Mild & Moderate) Compared to Subjects With Normal Renal Function | |
| Phase 1Completed | 4 Feb 2022 | Study to Investigate Drug-Drug Interaction Between MT-7117 and Test Drugs in Healthy Subjects | |
| Phase 1Completed | 23 Feb 2022 | Study to Evaluate the Effect of a Single Oral Dose of MT-7117 on the QT/QTc Interval in Healthy Subjects | |
| Phase 1Completed | 21 Jul 2025 | The Purpose of This Study is to Investigate the Safety, Tolerability and Pharmacokinetics of MT-7117 in Healthy Subjects. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026